Back to Journals » Patient Related Outcome Measures » Volume 2

Antiplatelet therapy in acute coronary syndromes: current agents and impact on patient outcomes

Authors Tayeb HM, Nelson AJ, Willoughby SR, Worthley M

Published 30 December 2010 Volume 2011:2 Pages 7—19


Review by Single anonymous peer review

Peer reviewer comments 2

Hussam M Tayeb, Adam J Nelson, Scott R Willoughby, Matthew I Worthley
Cardiovascular Research Centre, Royal Adelaide Hospital and Discipline of Medicine, University of Adelaide, Adelaide, South Australia, Australia

Abstract: Platelets play a central role in atherothrombosis and subsequent development of acute coronary syndromes (ACS). The understanding of this process has driven a large body of evidence demonstrating the mortality and morbidity benefits of antiplatelet agents in the ACS population. As expected, however, these agents come with an intrinsically increased risk of bleeding which underlies the vast majority of their complications and adverse effects. In today's setting of compounding comorbidities and broadening indications, finding the balance between thrombosis prevention and bleeding risk remains the challenge for all clinicians considering these medications. This article reviews the current main antiplatelet agents that are available for clinical use and outlines their impact on ACS outcome. We also outline factors which affect the response to these agents and discuss strategies to optimize clinical outcomes.

Keywords: antiplatelet, acute coronary syndromes, outcomes

Creative Commons License © 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.